Acar M et al. – The study demonstrated that MS patients treated with high–dose intravenous methylprednisolone (HIVMP) have increased intraocular pressure (IOP) which does not lead to conditions at risk for developing glaucoma.

• Forty patients with clinically definite MS admitted for a new demyelinating event were included in the study.
• All patients were treated with HIVMP (1 g) once daily for 5 consecutive days.
• IOPs of 40 patients were recorded before treatment, during the course of systemic methylprednisolone administration and at the end of each month for 3 successive months, four times a day.
• The average IOP of each day was statistically compared to the pretreatment value.

• The initial IOP was 13.5 ± 2.4 mm Hg before steroid administration.
• The IOP values tended to rise significantly during intravenous corticosteroid administration and in the first month of follow–up (p<0.05).
• However, the increase remained within normal ranges and IOP values never exceeded 20 mm Hg during the follow–ups.